



Application Serial No. 10/713424

Attorney Docket No. 6102-000071/US

Express Mail Label No. EQ 326178967 US

### Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as express mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On July 19, 2007  
Date

Signature

SUSAN B. GAWLIK

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Submitted herewith is (are):

Post Card

Supplemental Information Disclosure Statement (3 pgs)

Form PTO-1449 (5 pgs)

Cited documents (except U.S. patents and patent application publications)

Foreign Documents (13)

Other Documents (11)

Express Mailing Label (EQ 326178967 US)



07-20-07

*IFW*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant of: Li, *et al.*  
Serial No.: 10/713,424  
Filed: November 17, 2003  
Title: IONTOPHORETIC DELIVERY OF ROTIGOTINE FOR THE  
TREATMENT OF PARKINSON'S DISEASE  
Group Art Unit: 1617  
Examiner: Claytor, D.R.  
Confirmation No.: 4527  
Docket No.: 6102-000071/US  
Client Ref.: P/Wo/IX/12/02

**CERTIFICATE OF MAILING**

I certify that this paper, together with any attachments thereto, is being deposited with the United States Postal Service with sufficient postage as EXPRESS MAIL in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on July 19, 2007.

*Susan B. Gawlik*

Susan B. Gawlik

July 19, 2007

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant hereby submits a Supplemental Information Disclosure Statement (IDS) under 37 C.F.R. §1.97(c). Authorization provided herewith to charge the fee delivered under 37 C.F.R. §1.17(p) to Deposit Account No. 08-0750.

This IDS supplements that filed in the present application on February 16, 2004.

In accordance with 37 C.F.R. §1.97(g) and (h), this submission shall not be construed as representation that a search has been made or as admission that information presented or cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

In accordance with 37 C.F.R. §1.98, applicant submits herewith (1) a listing on Form

07/23/2007 TNGUYEN2 00000001 080750 10713424

01 FC:1806

180.00 DA

PTO-1449 of documents requested to be considered by the Examiner; and (2) a legible copy of each listed document, except for U.S. patents and U.S. patent application publications.

Applicant also submits herewith a copy of an International Search Report (ISR) and International Preliminary Examination (IPER) in International Patent Application No. PCT/EP 03/13111, which is a counterpart of the present application. All documents cited in the ISR and IPER are already of record in the present application or are now made of record by the present supplemental IDS.

In compliance with 37 C.F.R. §1.98(a)(3), Applicant provides the following statements of relevance, as presently understood by the individual designated in 37 C.F.R. §1.56(c) most knowledgeable of the contents of those documents listed on attached Form PTO-1449 (a) which are not in the English language and (b) full English language translations of which are not in Applicant's possession. Where a full or partial English language translation of a non-English language document is available to Applicant, a copy of such translation is included in the present submission. No representation is made as to accuracy of the translation or, in the case of partial translation, that all pertinent parts of a document have been translated.


DE 43 25 855. This publication appears to relate to benzoic acid derivatives having a generic formula as shown therein, and to a method for their preparation and application as drugs, for example for disease of the central nervous system such as psychoses, depression, anxiety and schizophrenia, and as a sedative. The subject compounds are said to show a postsynaptic dopamine-antagonist effect but a presynaptic dopamine-agonist effect. An English language translation of the title, abstract and a part of the specification (page 3, line 52 – page 4, line 2) is appended to the copy of DE 43 25 855 submitted herewith.

WO 2006/050976. This publication relates to a transdermal therapeutic system having a rotigotine-containing adhesive layer. Applicant is in possession of an English language translation, which is appended to the copy of WO 2006/050976 submitted herewith.

In accordance with 37 C.F.R. §1.98, Applicant submits herewith a listing on Form PTO-1449 of documents requested to be considered by the Examiner.

Serial No. 10/713,424  
6102-000071/US  
Supplemental IDS  
July 19, 2007

Respectfully submitted,  
HARNESS, DICKEY & PIERCE, P.L.C.



James C. Forbes  
Agent for Applicant  
Reg. No. 39,457  
Tel. 847-412-6350

Address Correspondence to:  
Harness, Dickey & Pierce, P.L.C.  
7700 Bonhomme, Suite 400  
St. Louis, MO 63141

Attachments  
Form 1449 (1 page)  
Cited documents (except U.S. patents and patent application publications)  
Foreign Documents (13)  
Other Documents (11)



FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Sheet 1 of 5

ATTORNEY DOCKET NO.	SERIAL NO.
6102-000071/US	10/713424
APPLICANT	
Li et al.	
FILING DATE	GROUP
November 17, 2003	1617

U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Name	Class/ Subclass	Filing Date
		4,801,586	Jan 31, 1989	Minaskanian et al.	514/212	Oct 07, 1986
		4,808,414	Feb 28, 1989	Peck et al.	424/449	Nov 19, 1986
		4,847,253	Jul 11, 1989	Buonamici et al.	514/253	Nov 18, 1988
		4,917,896	Apr 17, 1990	Peck et al.	424/449	Nov 19, 1986
		5,034,386	Jul 23, 1991	Peck et al.	514/212	Aug 17, 1988
		5,043,441	Aug 27, 1991	Peck et al.	540/526	Jan 22, 1990
		5,069,909	Dec 03, 1991	Sharma et al.	424/449	Jun 20, 1990
		5,071,645	Dec 10, 1991	Johnson et al.	424/486	Mar 20, 1991
		5,071,875	Dec 10, 1991	Horn et al.	514/613	Sep 25, 1989
		5,073,544	Dec 17, 1991	Peck et al.	514/24	Mar 23, 1989
		5,108,991	Apr 28, 1992	Rajadhyaksha	514/29	Dec 31, 1985
		5,118,845	Jun 02, 1992	Peck et al.	564/215	Jan 22, 1990
		5,142,044	Aug 25, 1992	Minaskanian et al.	540/529	Jan 22, 1990
		5,151,446	Sep 29, 1992	Horn et al.	514/617	Mar 28, 1991
		5,204,339	Apr 20, 1993	Minaskanian et al.	514/182	Aug 06, 1990
		5,234,945	Aug 10, 1993	Belluzzi	514/438	Jan 04, 1991
		5,271,940	Dec 21, 1993	Cleary et al.	424/448	Mar 27, 1992
		5,273,756	Dec 28, 1993	Fallon et al.	424/448	Aug 23, 1991
		5,308,625	May 03, 1994	Wong et al.	424/449	Sep 02, 1992
		5,382,596	Jan 17, 1995	Sleeve et al.	514/459	Aug 05, 1993
		5,456,745	Oct 10, 1995	Roreger et al.	106/128	Aug 11, 1989
		5,472,946	Dec 05, 1995	Peck et al.	514/29	Aug 06, 1993
		5,519,034	May 21, 1996	Kozlik et al.	514/307	Aug 18, 1994
		5,532,278	Jul 02, 1996	Aberg et al.	514/617	Jan 31, 1995
		5,601,839	Feb 11, 1997	Quan et al.	424/448	Apr 26, 1995
		5,670,164	Sep 23, 1997	Meconi et al.	424/448	Sep 29, 1995

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Sheet 2 of 5

ATTORNEY DOCKET NO.

SERIAL NO.

6102-000071/US

10/713424

APPLICANT

Li *et al.*

FILING DATE

GROUP

November 16, 2003

1617

**U.S. PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Name	Class/ Subclass	Filing Date
		5,670,501	Sep 23, 1997	Peck et al.	514/234.2	Sep 01, 1994
		5,677,346	Oct 14, 1997	Aberg et al.	51/617	Jun 07, 1995
		5,688,524	Nov 18, 1997	Hsu et al.	424/449	Mar 10, 1993
		5,771,890	Jun 30, 1998	Tamada	128/635	Jun 24, 1994
		5,807,570	Sep 15, 1998	Chen et al.	424/449	Sep 04, 1996
		5,834,010	Nov 10, 1998	Quan et al.	424/448	Jan 03, 1997
		5,840,336	Nov 24, 1998	Hsu et al.	424/484	Jun 07, 1995
		5,876,746	Mar 02, 1999	Jona et al.	424/449	Jun 06, 1996
		5,891,461	Apr 06, 1999	Jona et al.	424/449	Sep 14, 1995
		5,902,603	May 11, 1999	Chen et al.	424/449	Sep 13, 1996
		5,906,830	May 25, 1999	Farinas et al.	424/448	Sep 04, 1996
		5,962,013	Oct 05, 1999	Wong et al.	424/448	Aug 04, 1998
		5,981,524	Nov 09, 1999	Peck et al.	514/234.2	Aug 04, 1997
		6,010,716	Jan 04, 2000	Saunal et al.	424/449	Dec 03, 1997
		6,024,974	Feb 15, 2000	Li	424/448	May 27, 1997
		6,024,976	Feb 15, 2000	Miranda et al.	424/449	Aug 11, 1997
		6,057,371	May 02, 2000	Glennon	514/649	Jun 10, 1992
		6,063,398	May 16, 2000	Gueret	424/443	Sep 08, 1997
		6,086,905	Jul 11, 2000	Peck et al.	424/406	Aug 04, 1993
		6,218,421	Apr 17, 2001	King	514/421	Jul 01, 1999
		6,221,627	Apr 24, 2001	Sathe et al.	435/69.1	Feb 24, 1997
		6,242,572	Jun 05, 2001	Tsui et al.	530/350	Jun 04, 1999
		6,299,900	Oct 09, 2001	Reed et al.	424/449	Dec 18, 1998
		6,300,365	Oct 09, 2001	Holman	514/418	May 07, 2001
		6,344,342	Feb 05, 2002	Tsui et al.	435/69.1	Apr 18, 2001

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p><b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)</p> <p>Sheet 3 of 5</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000071/US	10/713424
	APPLICANT	
	Li et al.	
	FILING DATE	GROUP
	November 16, 2003	1617

U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Name	Class/ Subclass	Filing Date
		6,393,318	May 21, 2002	Conn et al.	604/20	May 11, 1999
		6,398,562	Jun 04, 2002	Butler et al.	439/91	Sep 17, 1999
		6,416,503	Jul 09, 2002	Suzuki et al.	604/501	Apr 24, 1997
		6,620,429	Sep 16, 2003	Müller	424/449	Jul 30, 2001
		6,685,959	Feb 03, 2004	Moreau et al.	424/449	Jan 30, 2002
		6,687,522	Feb 03, 2004	Tamada	600/347	Jun 28, 2001
		7,038,085	May 02, 2006	Rariy et al.	564/165	Oct 22, 2003
		2002/0010201	Jan 24, 2002	Brecht	514/388	Oct 04, 2001
		2002/0110585	Aug 15, 2002	Godbey et al.	424/449	Nov 30, 1999
		2003/0027793	Feb 06, 2003	Lauterback et al.	514/63	May 07, 2002
		2004/0057985	Mar 25, 2004	Bracht	424/449	Nov 24, 2001
		2004/0081683	Apr 29, 2004	Schact et al.	424/449	Jul 28, 2003
		2004/0110673	Jun 10, 2004	Steinkasserer et al.	514/12	Mar 06, 2003
		2004/0142904	Jul 22, 2004	Rariy et al.	514/63	Oct 22, 2003
		2005/0032873	Feb 10, 2005	Hatzenbuhler et al.	514/414	Jul 26, 2004
		2005/0033065	Feb 10, 2005	Mueller et al.	549/74	Sep 07, 2004
		2005/0079206	Apr 14, 2005	Schacht et al.	424/449	Jul 22, 2003
		2005/0107397	May 19, 2005	Galambos et al.	514/255.03	Sep 25, 2002
		2005/0182090	Aug 18, 2005	Mierau et al.	514/304	Jan 21, 2005
		2005/0197385	Sep 08, 2005	Scheller et al.	514/438	Feb 17, 2005

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)  <b>PATENT AND TRADEMARK OFFICE</b> <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)  Sheet 4 of 5	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000071/US	10/713424
	APPLICANT	
	Li <i>et al.</i>	
	FILING DATE	GROUP
	November 16, 2003	1617

FOREIGN PATENT DOCUMENTS							
Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Country	Class/ Subclass	Translation Yes	No
		CA 2532804	Feb 03, 2005	Canada	A61K 31/135		
		CA 2532859	Feb 03, 2005	Canada	A61K 31/381		
		CA 2546797	Jul 14, 2005	Canada	A61K 31/381		
		CA 2547820	Jun 30, 2005	Canada	A61K 31/135		
		CA 2568850	Feb 16, 2006	Canada	A61K 31/496		
		DE 4325855		Germany	CO7D 11/70	X	
		WO93/14727		PCT			
		WO93/16073		PCT			
		WO94/21244		PCT			
		WO94/26703		PCT			
		WO96/00110		PCT			
		WO05/063236		PCT			
		WO2006/050976	Mar 18, 2006	PCT	CO7D 471/04	X	

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
		Alekov <i>et al.</i> (2000) J. Physiology 529(3), 533-539
		Chiang <i>et al.</i> (1995) Controlled Release Society, Inc., pgs 710-711
		Holcomb <i>et al.</i> (1982) Eur. J. Pharmacol. 82, 173-178
		International Preliminary Examination Report for PCT/EP 03/13111
		International Search Report for PCT/EP 03/13111
		LeWitt <i>et al.</i> (2005) Adjunctive Treatment of Advanced Parkinson's Disease with Rotigotine Transdermal System (PREFER Study), LeWitt 1-25

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p><b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE CITATION</b>          (Use several sheets if necessary)</p> <p>Sheet 5 of 5</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000071/US	10/713424
	APPLICANT	
	Li <i>et al.</i>	
	FILING DATE	GROUP
	November 16, 2003	1617

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
		Nair <i>et al.</i> (1999) Methods Find Exp. Clin. Pharmacol. March 21(2), 139-151
		Ono <i>et al.</i> (1984) Neuropharmacol. 23(6), 637-642
		Polymeropoulos <i>et al.</i> (1997) Science 276, 2045-2047
		Roy & Flynn (1990) Pharmaceutical Research 7(8), 842-847
		Swart <i>et al.</i> (1992) International J. of Pharmaceutics, 88, 165-170

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.